View Archive »
About The Cover
The cover for issue 62 of Oncotarget features Figure 3, "High tumor load is associated with increased number of CD8+EOMEShigh T betlow cells," by Sponaas, et al.
|
|
Table of Contents
News
|
| Interplay between TRα1 and Wnt signaling: A dangerous liaison |
|
https://doi.org/10.18632/oncotarget.25807
|
| 31939-31940 |
|
| Thyroid hormone and intestinal tumor: a Wnt connection |
|
https://doi.org/10.18632/oncotarget.25822
|
| 31941-31941 |
Editorial
|
| Cancer and the junkyard chromosome: how repeat DNA sequence on chromosome 19 influences risk of malignant disease |
|
https://doi.org/10.18632/oncotarget.25873
|
| 31942-31944 |
Research Papers
|
| UHRF1 suppression promotes cell differentiation and reduces inflammatory reaction in anaplastic thyroid cancer |
|
https://doi.org/10.18632/oncotarget.10674
|
| 31945-31957 |
|
| Ponatinib exerts antiangiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway |
|
https://doi.org/10.18632/oncotarget.24110
|
| 31958-31970 |
|
| The assessment of correlation and prognosis among 18FFDG uptake parameters Glut1 pStat1 and pStat3 in surgically resected nonsmall cell lung cancer patients |
|
https://doi.org/10.18632/oncotarget.25865
|
| 31971-31984 |
|
| Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel |
|
https://doi.org/10.18632/oncotarget.25868
|
| 31985-31998 |
|
| Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progressionfree survival and time without treatment in patients with locally advanced pancreatic cancers |
|
https://doi.org/10.18632/oncotarget.25877
|
| 31999-32009 |
|
| PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.25880
|
| 32010-32023 |
|
| PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients |
|
https://doi.org/10.18632/oncotarget.25882
|
| 32024-32035 |
|
| Combinatorial engineering of NTIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell |
|
https://doi.org/10.18632/oncotarget.25885
|
| 32036-32053 |
|
| Circulating microRNA636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir |
|
https://doi.org/10.18632/oncotarget.25889
|
| 32054-32062 |
|
| Wildtype p53 oligomerizes more efficiently than p53 hotspot mutants and overcomes mutant p53 gainoffunction via a dominantpositive mechanism |
|
https://doi.org/10.18632/oncotarget.25944
|
| 32063-32080 |
|
| The efficacy and safety of firstline therapies for preventing chronic postsurgical pain: a network metaanalysis |
|
https://doi.org/10.18632/oncotarget.22611
|
| 32081-32095 |
Corrections
|
| Correction: MicroRNA expression in pretreatment plasma of patients with benign breast diseases and breast cancer |
|
https://doi.org/10.18632/oncotarget.25979
|
| 32096-32096 |
|
| Correction: Genetically enhanced T lymphocytes and the intensive care unit |
|
https://doi.org/10.18632/oncotarget.25983
|
| 32097-32097 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
